(Q36909996)

17 August 2017

1 reference

title

Plasmid DNA and viral vector-based vaccines for the treatment of cancer (English)

1 reference

17 August 2017

1 reference

Richard J Anderson

1

1 reference

17 August 2017

Joerg Schneider

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 June 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25 Suppl 2

1 reference

17 August 2017

page(s)

B24-34

1 reference

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

T-cell recognition of human melanoma antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Mechanisms of immune evasion by tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Strategies of tumor immune evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Human clinical trials of plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Preclinical and clinical safety studies on DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Direct transfection and activation of human cutaneous dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

DNA vaccines--back in the saddle again?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Recombinant viral vectors: cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Gene-based vaccines and immunotherapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Genetic stability of recombinant MVA-BN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Development and optimization of an adenovirus production process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Immunisation with canarypox virus expressing rabies glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Immunohistological distribution of 5T4 antigen in normal and malignant tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Applications of pox virus vectors to vaccination: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Development of adenovirus serotype 35 as a gene transfer vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Development of a preventive vaccine for Ebola virus infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

TRICOM vector based cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Development of the PANVAC-VF vaccine for pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

CTLA-4 blockade: unveiling immune regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Microparticle-based technologies for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Enhancement of DNA vaccine potency in rhesus macaques by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

DNA vaccines: recent developments and future possibilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

Chemical adjuvants for plasmid DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

DNA vaccines to attack cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.030

10.1016/J.VACCINE.2007.05.030

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference